Nazartinib mesylate

Catalog No. A21741

Nazartinib mesylate (EGF816 mesylate) is a novel, covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min?1 on EGFR(L858R/790M) mutant, respectively.
Catalog Num A21741
M. Wt 591.12
Formula C27H35ClN6O5S
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 1508250-72-3
Synonyms EGF816 (mesylate), EGF 816, EGF-816
SMILES O=C(C1=CC(C)=NC=C1)NC2=NC3=CC=CC(Cl)=C3N2[C@H]4CN(C(/C=C/CN(C)C)=O)CCCC4.CS(=O)(O)=O
Nazartinib mesylate (EGF816 mesylate) is a novel, covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min?1 on EGFR(L858R/790M) mutant, respectively.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 16.92 mL 84.59 mL 169.17 mL
0.5 mM 3.38 mL 16.92 mL 33.83 mL
1 mM 1.69 mL 8.46 mL 16.92 mL
5 mM 0.34 mL 1.69 mL 3.38 mL

*The above data is based on the productmolecular weight 591.12. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.